Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
Carmine De AngelisChandandeep NagiCliff C HoytLinying LiuKristin RomanNicholas WangYi ZhengJamunarani VeeraraghavanVidyalakshmi SethunathPaolo G NuciforoAnna TsimelzonSufeng MaoSusan G HilsenbeckMeghana V TrivediMaria Letizia CataldoAnne PavlickAntonio C WolffBritta WeigeltJorge S Reis-FilhoAleix PratCarolina GutierrezCharles Kent OsborneMothaffar F RimawiRachel SchiffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
LPBC was marginally associated with higher pCR rate than non-LPBC in patients with lapatinib plus trastuzumab treated HER2+ breast cancer. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response.